BlackRock’s Apogee Therapeutics APGE Stock Holding History
Bought
Maintained
Sold
Other funds holding APGE
BlackRock's APGE Position: Q3 2026 in Review
BlackRock sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 5,507,032 shares — an estimated $731M sold.
BlackRock first reported a position in APGE in Q3 2023 and held it in 12 quarters. The position peaked at $731M in Q2 2026. 3 funds tracked by Wall St. Rank hold APGE as of Q3 2026.
- BlackRock reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
- BlackRock sold 5,507,032 Apogee Therapeutics shares in Q3 2026, an estimated $731M.
- BlackRock first reported a position in Apogee Therapeutics in Q3 2023 and held it in 12 quarters.
- BlackRock's Apogee Therapeutics position peaked at $731M in Q2 2026.
- 3 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.
Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.